Ginkgo Bioworks Holdings (DNA) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Ginkgo Bioworks Holdings (DNA) overview

Ginkgo Bioworks Holdings (DNA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 170m and operating profit of USD -315m; the year-end share price was 8.31 USD and market capitalisation was USD 484m. Ginkgo Bioworks Holdings is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ginkgo Bioworks Holdings's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 509mFY 2025
Share price8.31 USDFY 2025 year end
RevenueUSD 170mFY 2025
Operating profitUSD -315mFY 2025
Net earningsUSD -313mFY 2025
Market capitalisationUSD 484mFY 2025 year end

About Ginkgo Bioworks Holdings

Ginkgo Bioworks provides biological research and development services and tools to government and commercial customers across medicine, agriculture, industrial biotechnology, and government research. Its cell engineering offerings include technical research services, laboratory automation and data generation tools, and licenses for host cells and other intellectual property. Its biosecurity business serves customers working to identify, monitor, prevent, and mitigate biological threats.

Generate the Ginkgo Bioworks Holdings report

Ginkgo Bioworks Holdings is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Ginkgo Bioworks Holdings and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Ginkgo Bioworks Holdings

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.